Prevention of Drug Access to Bacterial Targets: Permeability
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Some species of bacteria have low-permeability m e m b r a n e barriers and are thereby "intrinsically" resistant to many antibiotics; they are selected out in the multitude of antibiotics present in the hospital environment and thus cause many hospital-acquired infections. Some strains of originally antibiotic-susceptible species may also acquire resistance through decreases in the permeability of m e m b r a n e barriers. Another mechanism for preventing access of drugs to targets is the membrane-associated energy-driven efflux, which plays a major role in drug resistance, especially in combination with the permeation barrier. Recent results indicate the existence of bacterial efflux systems of extremely broad substrate specificity, in many ways reminiscent of the multidrug resistance pump of mammalian cells. One such system seems to play a major role in the intrinsic resistance of
P s e u d o m o n a s
a e r u g i n o s a , a common opportunistic pathogen. As the pharmaceutical industry succeeds in producing agents that can overcome specific mechanisms of bacterial resistance, less specific resistance mechanisms such as permeability barriers and multidrug active efflux may b e c o m e increasingly significant in the clinical setting.
Antibiotics have been highly effective in the treatment of infectious diseases, and the general population now expects that any bacterial infection will be cured easily by one of these agents. The emergence of resistant bacteria is changing this situation.
As described by Neu (l), patients in major hospitals staffed by highly competent personnel are dying as a resuh of infections by resistant bacteria. These resistant bacteria are of two kinds. First, the constant presence of antibiotics in the hospital environmenl has selected out the unaltered strains of those species that may not possess strong virulence but are intrinsically resistant to a number of antibiotics. These include Pseuda~nccma.~ aeruginosa and Enterococcus species, which infect debilitated patients in hospitals as "opportunistic pathogens." Second, there are those bacterial species that are well known for their pathogenicity. Many of these "professional pathogens" used to be ]he author is in the Deparlment of Molecular and Cell Biology, University of California, Berkeley, CA 94720-3206, USA.
exquisitely susceptible to antimicrobial agents. But many years of antihiotic usage have selected out drug-resistant strains, which either contain alterations in their chromosome or have acquired resistance plasmids (R plasmids) or resistance-conferring transposons from another organism.
Bacteria utilize several ingenious mechanisms to develop resistance. These include degradation of the drug, inactivation of the drug by enzymatic modification, and alteration of the drug target (2) . These mechanisms ate all quite specific for a single drug or a single class of drugs. There are, however, more general mechanisms of drug resistance, in which access of the unaltered agent to the target is prevented by the barrier and active transport functions of biological membranes. Thus, an organism can surround itself with a barrier of low permeability in order to decrease the influx of the drug into the cell and can also pump out the drug in an ener~,-dependent fashion. During the last few decades, the pharmaceutical industry has been successful in producing many synthetic and semisynthetic agents that are able to withstand the action of most of the enzymes that degrade or modify natural antibiotics. Because of this success, the less specific mechanisms such as the permeability barrier and the active efflux are likely to become more important in the clinical setting. Especially noteworthy is the recent observation, presented below, that some bacterial species already possess efflux transporters of very broad substrate specificity, reminiscent of the muhidrug resistance (mdr) pump of mammalian cells (3).
Bacterial Species Surrounded by Low-Permeability Barriers
Bacteria are unicellular organisms and their cytoplasm is separated from the external environment by the cytoplasmic membrane. The major permeability barrier in any membrane is the lipid bilayer structure, and its barrier property is inversely correlated with its fluidity (4). It is not possible to make the cytoplasmic membrane much less permeable, because this would require decreasing the membrane fluidity and interfeting with the proper functioning of membrane proteins. Thus, some bacteria protect themselves by constructing an additional structure that surrounds the cell, outside the cytoplasmic membrane. Most Gram-positive bacteria are surrounded by a thick peptidoglycan cell wall (Fig. 1 ). This structure, although mechanically strong, appears to offer little resistance to the diffusion of small molecules such as antibiotics, because its meshwork is too coarse (5) . In contrast, Gram-negative bacteria, such as Escherichia colt, surround themselves with a second membrane, the ,outer membrane, which functions as an effective barrier (Fig. 1) . The outer leaflet of the outer membrane bilayer is composed of an unusual lipid, lipopolysaccharide (LPS), rather than the usual glycerophospholipid found in most other biological membranes. Fatty acid chains present in LPS are all saturated. Because unsaturated fatty acid residues make the interior of the lipid bilayer fluid by preventing the tight a82 SCIENCE • VOL. 264 • 15 APRIL 1994 packing of the hydrocarbon chains (4), the absence of unsaturated fatt T acids is expected to make the interior of the I.PS leaflet much less fluid. In addition, an LPS molecule coratains six o~ seven covalently linked fatty acid chains, in c,mtrast to the glycerophospholipid that contains only two tarry acid residues. In general, a larger number of hydrocarbon chains linked to a single head group decreases the fluidity of the lipid interior (6) . Indeed, the interior of LPS bilayer structure has been shon'n experimentally to have very Ion' fluidi B' (or high order) (7), and hydropbobic probe molecules have been shown to partition poorly into the hydrophobic portion of LPS and to permeate across the outer membrane bilayer at about one-fiftieth to one-hundredth the rate through the usual phospholipid bilayers (8) .
The vast majority of clinically important antibiotics and chemotherapeutic agents shon' some hydrophobicity, which allows them to diffuse across the lipid bilayers of the cytoplasmic membrane. ]Prominent exceptions inch]de fosfi~mycin and aminoglycosides (such as streptomycin) (9) .] Compounds with multiple protonation sites are usually thought to exist in charged forms, but considerable anaounts may exist in uncharged forms (lO) that are able to diffuse across the bilayer. Clearly, the LPS-containing asymmetric bilayer of the bacterial outer membrane serves as an efficient barrier against rapid penetration by these lipophilic antibiotics and chemotherapeutic agents.
Bacteria surrounded by such an effective barrier, however, must develop a separate mechanism to bring in essential nutrients from the external medium. For this purpose, the outer membrane contains proteins of a special class, porins, which produce nonspecific aqueous diffusion channels across the membrane (II). The properties of the porin channels contribute to the exclusion of antibiotics in several ways. In E. coli, the most constricted portion of the channel has an opening of only 7 by 10 ~ (12), which makes the influx of many antibiotics nearly impossible or extremely slow. Furthermore, the t~nstriction is lined nith a number ot charged anaino acid residues, n'hich orient the water molecule., in a fixed direction. This makes entrance oflipophilic molecules into the constriction difficuh, because it disturbs this energetically favorable orientation of water (13) .
In spite of this arrangement, relatively hydmphilic agents, such as certain semisyntt)etic 13-1actams, can readily penetrate thrnugh the porin channels of enteric bacteria (14) . A different strate~, is adopted by another Gram-negative soil organism, P.
aeruunosa. This organism totally lacks the "classical" high-pemaeability potins that are present in most other Gram-negative bacteria, and is left only nith a low-efficiency porin that allows the diffusion ot small molecules at about one-hundredth the rate through the classical porin channels (15) .
Thus, hydrophilic antibiotics diffuse hcross the outer membrane of this organism only very slowly (15) , and the organism is thus "intrinsically resistant" (that is, resistant n'ithoul any chromo~maal mulatic~n or the acquisition of R plasmids) to a n, ide variety of cornmonly used antibiotics. On the other hand, even such an organism must take up essential nutrients, and for this purpose the P. aeruginosa outer rnembrane contains a number of special channels, each facilitating the diffusion of a specific class of compounds (•6).
Mycobacteria, Gram-positive bacteria phylogenetically remnte from P. aeruginosa, have adopted a similar st rate D, of surrounding themselves with a barrier of generally Ion, permeability. These bacteria are again intrinsically resistant to most antibiotics and pose a major public health problem when they develop resistance to the few available antimycobacterial agents, as occurred with the recent emergence of multiply drug-resistant tubercle bacillus (17).
The mycobacterial barrier also appears to consist of a lipid bilayer of unusually high order, and thus presumably low fluidity (18) (Fig. 1) . As with the outer membrane of Gram-negative bacteria, one of the leaflets conHsts of an unusual lipid. The fluidic" in this case is expected to be even lower than in the I_PS leaflet, because the main fauT acid in dw mycobacterial cell wall is mycnlic acid, which contains more than 70 carbon at~nls n'ith only a few double bonds. In LPS, six or seven fat~" acids were joined to a single head group; here, hundreds of mycolic acid residues are covalently linked to a common head group, an arabinogalactan polysaccharide, which in turn is covalently linked to the underlying peptidoglycan structure (I 9). The influx of nutrients is apparently carried out by the mycobacterial porin, which is present in very small amounts and allows only very slow difl-usion of small molecules through its channel (20) . The low permeabili~' of boda the lipid matrix and of the porin channel results in the very slow penetration by anubiofics. The diffusion rate of 13-1actam antibiotics, for example, is even slower, by a facto! of 10 or more, than the rates found in
P. aerugnmsa (2 I).

Resistance Caused by Decrease in Outer Membrane Permeability
Even organisms normally surrounded by a cell envelope of relatively high permeability can develop resistance by decreasing the permeability of the envelope (22) . When an agent mainly diffuses across the barrier through a specific channel, mutational loss of the channel can be an efficient mechanism for resistance. A "nonclassical" 13-1ac-tam compound, imipenem, shows an exceptional activity against P. aeruginosa, mainly because this agent diffuses through a specific channel, OprD, whose physiological function appears to be that of the transport of basic amino acids (23) . But this meant that P. aeruginosa could become resistant to imipenem by simply losing the OprD channel (24) , and currently a large fraction of P. aeruginosa strains isolated from the hospital environment are resistant as a result of this mechanism. In a similar manner, J3-1actam compounds designed to mimic iron-chelating compounds (siderophores) during their transport through the outer membrane are known to select mutants that are defective in the specific transport of these siderophores (25) . Mutations producing reduced expression of nonspecific porin genes can also make Gram-negative organisms significantly more resistant to certain agents. Such mutations are readily selected in the laboratory and have been reported in some clinical isolates (22) .
Permeation Barrier Alone Rarely Produces Significant Resistance
Surprisingly, mutants with decreased expression of porins are not very resistant to certain antibiotics. For example, in E. coli the minimal inhibitory concentration (MIC) for tetracycline increases by only 50% after the loss of porins (26) , and that for cefotaxime (a 13-1actam compound only slowly hydrolyzed by the 13-1actamase commonly found in Gram-negative bacteria) increases by only 100%, in contrast to an 8-to 32-fold increase in the MIC for cephalothin (a ~-lactam rapidly hydrolyzed by the same enzyme) (27) . This occurs because even the most effective permeability barrier of bacteria cannot completely shut out the influx of small molecules. Experimental data show that the half-equilibration time for hydrophilic ~-lactams across the outer membrane is less than 1 second in E. coli (22) . Thus, decreasing the outer membrane permeability further, say to 1% of the initial value, by decreasing the porin content will still produce a halfequilibration time of a few minutes. In other words, the drug will penetrate rapidly enough to exert its action. Similarly, even the low-permeability outer membrane of P. aeruginosa cannot prolong the half-equilibration time of most hydrophilic antibiotics beyond several minutes (22) .
The half-equilibration times mentioned above suggest that achievement of significant levels of drug resistance requires a second contributor in addition to a lowpermeability barrier. Escherichia coli does not inactivate tetracycline and it hydrolyzes cefotaxime only slowly; for these agents the second contributor is essentially absent, and thus decreased outer membrane permeability has little effect on MIC. In contrast, the hydrolytic inactivation of the agents by 13-1actamase, located in the periplasm (the space between the outer and cytoplasmic membranes; see Fig.  1 ), functions as an effective second factor for readily hydrolyzed ~-lactams, such as cephalothin, in E. coli. The two contributors, the outer membrane and 15-1actam-ase, work together synergistically, because under these conditions the enzyme can produce significant resistance by hydrolyzing only the small number of 13-1actam molecules that slip through the outer membrane barrier (22, 28) . When the hydrolysis occurs efficiently, the permeability barrier becomes a limiting step tn the overall degradation of drugs by intact bacteria, and thus decreases in porin level have pronounced effects on MIC, as described above for cephalothin.
Active Efflux as a Mechanism of Drug Resistance
Resistance caused by the active pumping out, or transmembrane efflux, of noxious agents began to attract the attention of scientists around 1980, when S. B. Levy and co-workers showed that plasmid-coded tetracycline resistance of E. coli (29) is based on energy-dependent efflux. This was followed shortly afterward by the demonstration that the plasmid-coded cadmium resistance of Staphylococcus aureus was also based on an et~lux mechanism (30) . Active drug efflux systems in bacteria (31) can be divided into four families (Table 1 ) on the basis of supramolecular assembly, mechanism, and sequence homology: (i) "major facilitator (MF) family" (32) , which shows sequence homology to the glucose facilitators of mammalian cells and also includes drug effllux proteins of eukaryotic microbes--for example, ATR-1 of yeast (33); (ii) resistance-nodulation-division (RND) family (34) , which also includes transporters that pump out cadmium, cobalt, and nickel ions (34); (iii) Smr or staphylococcal multidrug resistance fam- (32, (34) (35) (36) .
There is little sequence homology between MF and RND proteins, although both are composed of two homologous halves, each usually containing six transmembrane helices (32, 34, 36) . Efflux transporters of the MF family are different from the transporters involved in nutrient uptake, in that they contain the consensus sequence G-X-X-X-G-P-X-X-G-G (37) . Furthermore, same efflux transporters of the MF family (including QacA, Mmr, EmrB, and ActlI) are predicted to contain 14, rather than 12, transmembrane e~ helices (37) . It is increasingly reco~lized that active efflux plays a major role in the resistance of many organisms to many agents (31); among the three clinically relevant resistance mechanisms listed by Neu (1) as involving reduced pemleabiliB-, two, and possibly all three, are mainly due to efflux. (i) Beginning with the demonstration, by Neal and Chater in 1987 (38) , that Streptomyces coelicolor protects itself fi-om the methylenomycin it produces, a number of antibiotic efflux genes have been identified in antibiotic-producing Streptomyces species. Some of them belong to the MF family and others to the ABC family. (ii) A new type of plasmid-mediated macrolide resistance in S. aureus, which was originally thought to be due to decreased permeabili~,, was shown to involve active efflux (39) . ( iii) The commonest mechanism of chloramphenicol resistance involves the em3,matic acetylation of the drug. The "nonenzymatic mechanism of chloramphenicol resistance," again originally thought to be due to decreased influx of chloramphenicol (40) , was shown to be caused by active efflux, because the cm/A gene from transposon Tn1696 appears to be an active efflux transporter of MF family (41, 42) . Furthermore, Haemophilus influenzae contains a homologous chromosomal gene (41) , and thus the nonen:3,nlatic resistance of this (and perhaps many other) species is very likely due to active efflux. (ix,) Plasmidocoded resistance to quaternary ammonium antiseptics in staphylococci was shown to involve efflux, through the QacA-QacB transporter of MF type and the QacC transporter of Shy type. These proteins also pump out some basic dyes (Table 1) . (v) Active efflux of norfloxacin, a fluoroquinolone, was first discovered in wild-type E. coli (43) . A gene (TwrA) involved in a similar active efflux process was later sequenced from the chromosome of a resistant mutant ofS. aure~¢s and was shown to code for an effiqux transporter of the MF family (44) . NorA pumps out a variety of fluoroquinolones (44, 45) .
Multidrug Efflux Systems in Bacteria
An exciting development in this field has been the discovery of bacterial efflux systems that can handle a wide variety of drugs (46) (57) .
The genetic identity of this efflux system was suggested by the study of K. Poole and associates (58) . In their study of Fe 3+ uptake in P. aeruginosa, they cloned an operon, mexA-nvexB-oprK, which is believed to function in the export of the siderophore pyoverdine. MexB has a typical sequence for an RND family transporter. When this operon was inactivated by insertion mutagenesis, the P. aerugi+msa strain became almost as susceptible as E. coli to both chloramphenicol and tetracycline (58) . This suggests that this single efflux system is the major reason that this species displays the generally drug-resistant phenotype.
But how do we explain the resistance to 13-1actams? Pseudomonas aeruginosa produces a chrojnosomally coded, inducible ~-lactamase, and the synergy between this enzyme and the outer membrane barrier explains its resistance to some compounds that act as strong inducers of this em3~e (59) . However, strains with a high intrinsic resistance are also highly resistant to compounds that do not induce much IB-lactamase and are quite stable to enzymatic hydrolysis. Further, these strains are unaltered in their targets of ]3-1actam action or in the Our resuhs indeed indicate that their ~-lactam resistance is also caused by active eMux (57) . Unlike ~ther hy&ophobic agents, however, some 6-1actams carmot cross the cytoplasmic membrane barrier (57) , and their targets are on the periplasmic side of the cytoplasmic membrane. How could the effflux system help? It is usefiJl here to recall that the mammalian mdr protein apparently intercepts its substrate during its transit through the lipid bilayet. Our observation on bilayet-impermeant ~3-1actams gives strong support to this idea (Fig. 2) . The apparently wide substrate specifici~, of the P. ueruginosa el flux system is somewhat surprising. We should again recall that the mammalian mdr pump extrudes not only basic compounds, such as doxorubicin, but also neutral compounds, such as taxol, and weakly acidic comp~unds, such as mithramycin (3). Indeed, the mammalian mdr purnp is inhibited by hydrophobic cephalosporins, which presumably act as substrate analogs (3).
The Efflux System and the Outer Membrane Barrier
Efflux transporters are located in the cytoplasmic membrane, and thus in Gram-negative bacteria the agents may be assumed to be pumped out into the periplasm (see Fig.  1 ). lfso, the effllux is unlikely to make these bacteria more resistant, because the antimicrobial agents will not be able to leave the cells easily owing to the presence of the outer membrane barrier. One way to overcome this barrier was suggested by the presence of accessory proteins that occur together with many efflux transporters of both MF and RND families in Gram-negative cells (Table 1) . These proteins are thought to "bridge" the cytoplasmic transporter and an outer membrane channel so that the drugs can be extruded directly into the surrounding medium rather than into the periplasm (Fig. 2) , as they are related to a group of proteins in Gram-negative bacteria, including HlyD, LktD, CyaD, AprE, and CvaA (34), which similarly act as bridges and help extrude their substrates, proteins, directly into external media (60) . It is thus likely that the accesso~' proteins form complexes with sorne channel proteins in the oute/membrane, for example, TolC ~,~0). This model was supported recently by the discovery of the mexA-mexB-oprK system of P. aeruginosa (58) . This presumed operon codes not on]y for an accessory protein MexA but also for an outer membrane protein OprK, and this gene organization suggests that the three proteins form a complex that likely forms a continuous channel opening into the external medium (Fig. 2) . Indeed, OprK shows sequence homolo~, with CyaE and PrtF (58), outer membrane proteins that are presumably involved in the formation of three component export complexes containirlg { transporter in the cytoplasmic protein, a periplasmic accessory protein, and an outer membrane channel, which function in the direct export of cyclolysin and proteases B
and C into the medium in Bordetella perzussis and Erwinia chrysanthemi, respectively {60). Furtherrnore, inactivation of OprK led to hypersusceptibility to many agents, just like the inactivation of MexA (58). We do not yet know how the systems that do not contain accessory proteins extrude the agents efficiently mto the medium. As mentioned, the low permeability of the outer membrane alone is not likely to produce clinically significant levels of resistance, and a second contributor is needed for this purpose. In many systems, the active efflux system appears to be this second factor. But this does not mean that the outer membrane barrier is not important. Because the intracellular concentration of any drug is the resuh of a balance between influx and efflux, it is likely that the slow influx of various agents through the lowpermeability outer membrane makes efflux an especially effective mechanism for resistance in P. aeruginosa. That (62). This ability of some plasmid-or transposon-based efflux genes to decrease outer membrane permeability has been seen so far only with resistance determinants of a narrow range. It would create a major heahh-care problem if such an activity were to become combined with broad substrate profile efflux transporters.
Increased expression of efflux transporters, often accompanied by the repression of OmpF porin synthesis, may occur without any genetic alteration. Thus, chloramphenicol and tetracycline increase the transcription of MarA regulatory protein (55) , thereby presumably increasing the synthesis of the efflux transporter or transporters. Interestingly, oxygen stress, to which pathogenic bacteria are exposed in host tissues, is known to produce OmpF repression with increased resistance to several agents (63) , possibly as a resuh of increased efflux. Similarly, salicylate, which is produced in plant tissues in response to the invasion by microorganisms (64) , is known to repress the synthesis of OmpF porin and to make E. colt transiently more resistant to ghloramphenicol, tetracycline, quinolones, and ampicillin (64) . This range of agents is again suggestive of the involvement of an efflux system or systems.
Because specific mechanisms of antibiotic resistance were thought to be more important, efforts to produce more effective antibiotics have usually involved modification of specific groups on antibiotic molecules in order to make them inert as potential substrates for commonly occurring anfibiotic-mactivating en:ymes. The presence of the more general mechanisms of resistance, discussed in this article, forces us to reevaluate this strate~'. These mechanisms produce clinically significant resistance: The intrinsic resistance to a wide variety ot antibi~Ttics seen in the importanl opportunistic pathogen, P. aeruginosa, is indeed due to a combination ot a muhidn]g efflux transporter and an effective permeability barrier, and increased expression of the efflux transporter is the most probable cause of resistance in most of the clinical isolates from the British Isles showing increased levels ofcarbenicillin resistance (56, 57) . It will be a major challenge fi,r the pharmaceutical industry to produce compounds that are able to overcome mechanisms of this type, because some of the multidrug eff]ux system seems to pump out almost an}' amphiphilic compound (05). Obviously, we need to obtain more knowledge about the substrate-binding process of these transporters. Another possible approach would be to increase the spontaneous influx of drugs--for example, by making the drug sufficiently lipophilic so that efflux can be counterbalanced by rapid influx. Indeed, more lipophilic derivatives of tetracycline and fluoroquinolones are more active on resistant strains of Gram-positive bacteria that pump out these agents (10) . In Gramnegative bacteria, however, more lipophilic agents will be slower in traversing the porin channel, and increased lipophilicity may not increase the efficacy of the agents.
Resistance to Antibiotics Mediated by Target Alterations Brian G. Spratt
The d e v e l o p m e n t of resistance to antibiotics by reductions in the affinities of their enzymatic targets occurs most rapidly for antibiotics that inactivate a single target and that are not analogs of substrate. In these cases of resistance (for example, resistance to rifampicin), numerous single a m i n o acid substitutions m a y provide large decreases in the affinity of the target for the antibiotic, leading to clinically significant levels of resistance. Resistance due to target alterations should occur much m o r e slowly for those antibiotics (penicillin, for example) that inactivate multiple targets irreversibly by acting as close analogs of substrate. Resistance to penicillin because of target changes has e m e r g e d , by unexpected m e c h a n i s m s , only in a limited n u m b e r of species. However, inactivating e n z y m e s c o m m o n l y provide resistance to antibiotics that, like penicillin, are derived from natural products, although such e n z y m e s have not been found for synthetic antibiotics. Thus, the ideal antibiotic would be produced by rational design, rather than by the modification of a natural product.
The widespread use and misuse of antibiotics imposes immense selective pressures for the emergence of antibiotic-resistant bacteria, and as a consequence the development of antibiotic resistance is inevitable. For those antibiotics that are derived from natural products, resistance is most commonly due to the acquisition of genes encoding enzymes that inactivate the antibiotic, modify its target, or result in active efflux of the antibiotic (I). These resistance genes are believed to have evolved hundreds of millions of years ago in soil bacteria, either as protection from antibiotics produced by other soil bacteria or as protection for antibiotic-producing soil bacteria against their own antibiotics (2). Enzymes that inactivate synthetic antibiotics such as quinolones, sulfonamides, and trimetho-
The author is in the Microbial Genetics Group, School of Biological Sciences, University of Sussex, Falmer, Brighton BN1 9QG, U.K. prim have not been found, and for these antibiotics and those natural products where inactivating or modifying enzymes have not emerged (for example, rifamycins), resistance usually arises by target modifications (3) (4) (5) (6) .
Several types of target modification are found in antibiotic-resistant clinical isolates of bacteria. Resistance to a few antibiotics occurs by the acquisition of a gene encoding a new target enzyme that has much lower affinity for the antibiotic than the normal enzyme does. Resistance to sulfonamides and to trimethoprim, which inhibit dihydropteroate synthase and dihydrofolate reductase, respectively, is usually achieved by this mechanism (4, 5) . Methicillin resistance in Staphylococcus aureus also involves this mechanism (7) . In all of these examples, the source or sources of the antibiotic-resistant target enzymes is unclear. Production of increased amounts of normal target enzymes can also provide resistance (for example, as in a minority of trimethoprim-resistant clinical isolates of enteric bacteria) (5) .
However, the most common mechanism of resistance is the development of altered forms of the normal targets that have increased resistance to antibiotics. Such resistance may involve the acquisition of new genes, almost invariably carried on plasmids or transposons, that result in enzymatic modification of the normal target so that it no longer binds the antibiotic [for example, resistance to macrolide antibiotics by methylation of 23S ribosomal RNA (rRNA)] (8). Alternatively, resistance may result from mutational (or recombinational) events that lead to the development of antibiotic-resistant forms of the normal targets.
Here, I will focus on this latter mechanism, and particularly on resistance due to the development of altered target enzymes that have a reduced affinity for antibiotics. I will not discuss resistance due to ribosomal mutations (8) , not only because ribosomes are not enzymes in a strict sense, but also because this type of resistance is ofdoubtfial clinical significance almost all examples of resistance to antibiotics that act on the ribosome involve the acquisition of genes that either result in the protection of the ribosomes from the antibiotics or that inactivate the antibiotics (8) . The development of enzymatic targets with reduced affinity for antibiotics is a major mechanism of resistance when inactivating or modifying enzymes are absent. This includes resistance to rifamycins and quinolones (3, 6) and to l~-lactam antibiotics in species where [3-1actamases are absent (7) . Most of my review here will focus on resistance to [3-1actam antibiotics, for this provides a particularly instructive example of resistance that is the result of modification of enzymatic targets.
